Characterization of the impact of immune checkpoint inhibitors on platelet activation and aggregation.

[1]  Guang Xin,et al.  PD-L1 Regulates Platelet Activation and Thrombosis via Caspase-3/GSDME Pathway , 2022, Frontiers in Pharmacology.

[2]  L. Zender,et al.  Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer , 2021, Nature Communications.

[3]  S. Tasaka,et al.  Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report , 2021, Thoracic cancer.

[4]  J. Barnholtz-Sloan,et al.  Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries , 2021, Cancer medicine.

[5]  C. Berking,et al.  Inflammatory markers in autoimmunity induced by checkpoint inhibitors , 2021, Journal of Cancer Research and Clinical Oncology.

[6]  A. Khorana,et al.  Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy. , 2021, Med.

[7]  Y. Osamura,et al.  Acquired amegakaryocytic thrombocytopenia after durvalumab administration , 2021, Journal of clinical and experimental hematopathology : JCEH.

[8]  A. Khorana,et al.  Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival , 2021, Journal for ImmunoTherapy of Cancer.

[9]  M. Preusser,et al.  Incidence, risk factors and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. , 2020, Blood.

[10]  B. Gazzard,et al.  HIV Antivirals Affect Endothelial Activation and Endothelial-Platelet Crosstalk , 2020, Circulation research.

[11]  V. Ivaturi,et al.  Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Jahr,et al.  Platelet Function: Meloxicam Intravenous in Whole Blood Samples From Healthy Volunteers , 2020, Clinical pharmacology in drug development.

[13]  C. Nielsen,et al.  The effect of mycophenolate mofetil on platelet function. , 2020, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[14]  Kongming Wu,et al.  Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 , 2019, Molecular Cancer.

[15]  J. Aerts,et al.  A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients , 2019, Journal of Immunotherapy for Cancer.

[16]  B. Payrastre,et al.  Platelets Are Critical Key Players in Sepsis , 2019, International journal of molecular sciences.

[17]  K. Machlus,et al.  Modulation of megakaryopoiesis and platelet production during inflammation. , 2019, Thrombosis research.

[18]  Y. Tomita,et al.  Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies , 2019, Journal of clinical medicine.

[19]  T. Sage,et al.  Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction , 2018, Platelets.

[20]  M. Monteiro,et al.  Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases , 2018, Case Reports in Oncology.

[21]  P. Metharom,et al.  Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment , 2018, Cancers.

[22]  Lieping Chen,et al.  A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization , 2018, Cell.

[23]  D. Stolz,et al.  Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation , 2018, Haematologica.

[24]  B. Wollenberg,et al.  PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy , 2018, Oncotarget.

[25]  D. D. de Alwis,et al.  Evaluation of dosing strategy for pembrolizumab for oncology indications , 2017, Journal of Immunotherapy for Cancer.

[26]  K. Jurk,et al.  Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. , 2017, Blood.

[27]  Albert Sickmann,et al.  Temporal quantitative phosphoproteomics of ADP stimulation reveals novel central nodes in platelet activation and inhibition. , 2017, Blood.

[28]  A. Rauch,et al.  Abacavir has no prothrombotic effect on platelets in vitro. , 2016, The Journal of antimicrobial chemotherapy.

[29]  A. Korman,et al.  Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology , 2016, PloS one.

[30]  A. Drilon,et al.  Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer , 2016, Expert review of anticancer therapy.

[31]  R. Storey,et al.  The role of platelets in inflammation , 2015, Thrombosis and Haemostasis.

[32]  T. Biedermann,et al.  Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile , 2015, Ophthalmologica.

[33]  Junling Liu,et al.  Platelet Activation and Thrombus Formation over IgG Immune Complexes Requires Integrin αIIbβ3 and Lyn Kinase , 2015, PloS one.

[34]  M. Sliwkowski,et al.  Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) , 2014, Clinical Cancer Research.

[35]  A. Zarbock,et al.  Platelets in inflammation and immunity , 2014, Journal of thrombosis and haemostasis : JTH.

[36]  A. Korman,et al.  In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates , 2014, Cancer Immunology Research.

[37]  J. Wolchok,et al.  Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody , 2014, Science Translational Medicine.

[38]  A. Steinkasserer,et al.  Leukoreduction system chambers are an efficient, valid, and economic source of functional monocyte-derived dendritic cells and lymphocytes. , 2013, Immunobiology.

[39]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[40]  J. O’Leary,et al.  Increased platelet reactivity in patients with late-stage metastatic cancer , 2013, Cancer medicine.

[41]  K. Flaherty,et al.  Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[42]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[43]  S. Patel,et al.  Profile of ipilimumab and its role in the treatment of metastatic melanoma , 2011, Drug design, development and therapy.

[44]  S. O’Day,et al.  Phase I/II study of ipilimumab for patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  B. Furie,et al.  Mechanisms of thrombus formation. , 2008, The New England journal of medicine.

[46]  A. Khorana,et al.  Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients , 2008, Cancer.

[47]  Roberto Pili,et al.  Platelets Take Up the Monoclonal Antibody Bevacizumab , 2007, Clinical Cancer Research.

[48]  A. Varki.  Trousseau's syndrome: multiple definitions and multiple mechanisms. , 2007, Blood.

[49]  A. Khorana,et al.  Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy , 2007, Journal of thrombosis and haemostasis : JTH.

[50]  D. Shields,et al.  Monitoring modulators of platelet aggregation in a microtiter plate assay. , 2006, Analytical biochemistry.

[51]  Y. Merhi,et al.  Neutrophil P-selectin-glycoprotein-ligand-1 binding to platelet P-selectin enhances metalloproteinase 2 secretion and platelet-neutrophil aggregation , 2005, Thrombosis and Haemostasis.

[52]  Hui Zhang,et al.  Platelet activation leads to activation and propagation of the complement system , 2005, The Journal of experimental medicine.

[53]  C. A. de la Motte,et al.  Cutting Edge: T Cells Trigger CD40-Dependent Platelet Activation and Granular RANTES Release: A Novel Pathway for Immune Response Amplification1 , 2004, The Journal of Immunology.

[54]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[55]  E. Mammen,et al.  Preliminary Data from a Field Trial of the PFA-100™ System , 1995, Seminars in Thrombosis & Hemostasis.

[56]  P. Hjemdahl,et al.  Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.